Compare
Merck & vs Pfizer (MRK vs PFE)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year Merck & (MRK) returned +73.9% and Pfizer (PFE) +19.4%; so far this year the figures are +39.4% and +18.0%.
Merck & is the larger company by market value, about 2.2 times the size of Pfizer.
On trailing earnings, MRK trades at 149.7 times and PFE at 42.0 times.
Revenue grew +4.9% at MRK and +1.3% at PFE over the last year.
MRK yields 2.32%. PFE yields 5.85%.
Data as of the latest close. Not investment advice.
Relative performance
| MRK | PFE | |
|---|---|---|
| Price | $146.73 | $29.39 |
| 1-day | -0.14% | -1.64% |
| YTD | +39.40% | +18.03% |
| 1 year | +73.87% | +19.42% |
| 3 years | +42.66% | -3.67% |
| Market cap | $361.7B | $167.5B |
| P/E | 149.7 | 42.0 |
| P/S | 5.37 | 2.63 |
| P/B | 8.06 | 1.88 |
| Revenue growth | +4.90% | +1.30% |
| EPS growth | -87.10% | -59.30% |
| Gross margin % | 71.8 | 73.4 |
| Net margin % | 3.6 | 6.3 |
| ROE % | 5.5 | 4.5 |
| Debt / equity | 1.20 | 0.70 |
| FCF yield % | 4.1 | 7.0 |
| Dividend yield % | 2.32 | 5.85 |
| Beta | 0.18 | 0.26 |
| RSI (14) | 51.3 | 49.5 |
| Technical rating |